Italia markets closed

Novartis AG (NOVN.SW)

Swiss - Swiss Prezzo differito. Valuta in CHF.
Aggiungi a portafoglio
73,57-0,23 (-0,31%)
Alla chiusura: 05:30PM CET
Schermo intero
Chiusura precedente73,80
Denaro73,56 x 0
Lettera0,00 x 0
Min-Max giorno73,40 - 74,26
Intervallo di 52 settimane73,01 - 86,92
Media Volume3.746.951
Beta (5 anni mensile)0,53
Rapporto PE (ttm)18,52
EPS (ttm)3,97
Prossima data utili02 feb 2022
Rendimento e dividendo (forward)3,00 (4,07%)
Data ex dividendo04 mar 2021
Stima target 1A93,04
  • GlobeNewswire

    Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms

    Focused medicines company delivering strong operational performanceBuilding depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint Confident to grow sales 4%+ CAGR through 2026*, driven by multi-billion dollar sales from Cosentyx®, Entresto®, Kesimpta®, Zolgensma®, Kisqali® and Leqvio®**Up to 20 new assets with >1-billion dollar sales potential, set to potentially be approved by 2026, to fuel further growth through 2030 and beyond Cosentyx met

  • GlobeNewswire

    New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio

    New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix® (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T cell therapies highlight the progress in developing the next generation T-Charge™ Platform Final analysis from Phase Ib study evaluating efficacy and safety of sabatolimab (MBG453) in combination with HMAs in patients with very high/high-risk MDS and AML 12-month data from Phase II study of iptacopan (L

  • GlobeNewswire

    Novartis to sell its Roche stake in a bilateral transaction to Roche

    Ad hoc announcement pursuant to Art. 53 LR Novartis and Roche agree a bilateral transaction for the sale of Roche bearer shares held by Novartis for a total consideration of USD 20.7 billion Price of USD 388.99 per share (CHF 356.93 per share) reflects the volume-weighted average price of the Roche non-voting equity certificates (Genussschein) over the last 20 trading days ending on November 2, 2021 Monetization consistent with Novartis strategy as a focused medicines company Use of proceeds wil